Asciminib clinical trials
Also written ABL001.
How each study uses asciminib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the asciminib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 29 Oct 2021 · SCEMBLIX · NDA 215358 (FDA, Drugs@FDA)
- European Union
- 25 Aug 2022 · Scemblix · EMEA/H/C/005605 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
33 studies that test it; most in 2021 (6); 2 more planned to start later
| Year | Studies |
|---|---|
| 2014 | 1 |
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 3 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 6 |
| 2022 | 4 |
| 2023 | 1 |
| 2024 | 4 |
| 2025 | 4 |
| 2026 | 6 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 16 · Other 19
Novartis Pharmaceuticals (16) · M.D. Anderson Cancer Center (5) · City of Hope Medical Center (2) · University of Jena (1) · University of Alabama at Birmingham (1) · Washington University School of Medicine (1) · Sunil G. Iyer (1) · Thomas Ernst, Prof. Dr. med. (1)
Often tested with
Tested in the same studies.
Imatinib (2) · Nilotinib (2) · Dasatinib (2) · Fludarabine (1) · Cytarabine (1) · Idarubicin (1) · Venetoclax (1) · Inotuzumab Ozogamicin (1)
Related medicines
As reviewed, each with the page that says it.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 5
Studies that test asciminib.
- Nov 2026ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CMLPhase 1 · Marlise Luskin, MD
- Dec 2026Phase II Study of Asciminib for Second-line Treatment of Chronic Phase Chronic Myeloid LeukemiaPhase 2 · M.D. Anderson Cancer Center
- Mar 2027Frontline Asciminib Combination in Chronic Phase CMLPhase 2 · University of Jena
- May 2027Phase I/II Study of the Combination of Blinatumomab and Asciminib in Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic LeukemiaPhase 1/2 · M.D. Anderson Cancer Center
- Sep 2027Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid LeukemiaPhase 1/2 · Novartis Pharmaceuticals
Studies
Open first, then newest update. How each study uses asciminib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 35
- Asciminib and Inotuzumab Ozogamicin for Relapsed or Refractory Philadelphia Chromosome-positive B-cell Acute Lymphoblastic Leukemia (R/R Ph+ B-ALL)RecruitingPhase 1Sunil G. IyerNCT07936266Written as Asciminib
- Phase I/II Study of the Combination of Blinatumomab and Asciminib in Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic LeukemiaRecruitingPhase 1/2M.D. Anderson Cancer CenterNCT06308588Written as Asciminib
- Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CPRecruitingPhase 2Novartis PharmaceuticalsNCT07354074Written as Asciminib single agent
- Efficacy of Asciminib in Chronic Phase CML Patients With T315I MutationsRecruitingPhase 2Thomas Ernst, Prof. Dr. med.NCT07789574Written as asciminib 200 mg BID
- Asciminib Roll-over StudyRecruitingPhase 4Novartis PharmaceuticalsNCT04877522Written as Asciminib single agent
- Asciminib-Based Induction Therapy for the Treatment of Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic LeukemiaNot yet recruitingPhase 1City of Hope Medical CenterNCT07914166Written as Asciminib
- Asciminib as Maintenance Treatment After Cellular Therapies for Adults With Philadelphia Chromosome Positive Acute Lymphoblastic LeukemiaRecruitingPhase 1City of Hope Medical CenterNCT07040982Written as Asciminib
- Phase 1/2 FLAG-IDA, VEN and Asciminib in CML and Ph+ AMLNot yet recruitingPhase 1/2M.D. Anderson Cancer CenterNCT07604233Written as Asciminib
- Phase II Study Assessing Efficacy and Safety of Asciminib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase.RecruitingPhase 2M.D. Anderson Cancer CenterNCT06236724Written as Asciminib
- Phase II Study of Asciminib for Second-line Treatment of Chronic Phase Chronic Myeloid LeukemiaRecruitingPhase 2M.D. Anderson Cancer CenterNCT06629584Written as Asciminib
- Asciminib With or Without Sildenafil for Brain TumorsNot yet recruitingEarly Phase 1Washington University School of MedicineNCT07039760Written as Asciminib
- Protocol Number: HJKC3-0003. Treatment Free Remission After Asciminib Based Therapy in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI DiscontinuationRecruitingPhase 2Medical College of WisconsinNCT04838041Written as Asciminib 40 MG
- Asciminib in HER2+ Breast Cancer Brain MetastasesRecruitingPhase 1/2Duke UniversityNCT07136428Written as Asciminib and Trastuzumab
- Open-label Study of Asciminib for CML-CP or CML-AP Patients With T315I Mutation Who Are Resistant, Intolerant or Ineligible to Ponatinib.RecruitingPhase 2Novartis PharmaceuticalsNCT06514534Written as ABL001/Asciminib
- A Study of Treatment-free Remission in Chronic Phase Chronic Myeloid LeukemiaRecruitingPhase 2Korean Society of HematologyNCT06368414Written as Asciminib
- Asciminib Maintenance Therapy Following alloHCT or CAR T to Prevent Relapse in Adults With Ph+ALLRecruitingPhase 1H. Lee Moffitt Cancer Center and Research InstituteNCT07250087Written as Asciminib
- ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CMLRecruitingPhase 1Marlise Luskin, MDNCT03595917Written as ABL001
- PEARL Study: PotEntial of Asciminib in the eaRly Treatment of CMLRecruitingPhase 2Gruppo Italiano Malattie EMatologiche dell'AdultoNCT06409936Written as Asciminib
- Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid LeukemiaActive, not recruitingPhase 1/2Novartis PharmaceuticalsNCT04925479Written as Asciminib Pediatric formulation group
- A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CPActive, not recruitingPhase 3Novartis PharmaceuticalsNCT04971226Written as Asciminib
See all 35 studies that test asciminib →
Given beside what is tested · 2 — asciminib is usual care or a partner of the new treatment
- Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL)RecruitingPhase 1/2Novartis PharmaceuticalsNCT07387926Written as Asciminib Adult formulation
- A Study of Full Treatment-free Remission in Patients With Chronic Myeloid LeukemiaTerminatedPhase 2Novartis PharmaceuticalsNCT03874858Written as Asciminib
What changed recently
From the registry's own updates since Oct 18, 2026.
Started recruiting1
- Efficacy of Asciminib in Chronic Phase CML Patients With T315I MutationsNov 10, 2026NCT07789574
Newly registered2
- Asciminib and Inotuzumab Ozogamicin for Relapsed or Refractory Philadelphia Chromosome-positive B-cell Acute Lymphoblastic Leukemia (R/R Ph+ B-ALL)Nov 13, 2026NCT07936266
- Asciminib-Based Induction Therapy for the Treatment of Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic LeukemiaNov 3, 2026NCT07914166
Codes
What other systems call asciminib · ClinicalTrials.gg INT000758
- MeSH (NLM) C000621806asciminibConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) L1F3R18W77ASCIMINIBConfirmed FDA, NLM, Wikidata
- RxNorm 2584304One source FDA
- Wikidata Q27074535asciminibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C114494AsciminibOne source FDA
- DrugBank DB12597One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000621806 | asciminib | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | L1F3R18W77 | ASCIMINIB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2584304 | — | One source FDA |
| Wikidata | Q27074535 | asciminib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C114494 | Asciminib | One source FDA |
| DrugBank | DB12597 | — | One source Wikidata |
Also registered as asciminib hydrochloride (UNII C5U34S9XFV · RxNorm 2584303).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.